Does a Wound-Healing gel raise cancer risk? new study aims to find out
NCT ID NCT06423573
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers want to see if using Filsuvez, a birch bark extract gel that helps heal blisters, changes the risk of developing skin cancer. Participants receive standard care, with or without Filsuvez, and are monitored for new skin malignancies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Filsuvez (birch bark extract gel)
- What this could lead to
- If it shows that Filsuvez does not increase skin cancer risk, it would support its safe long-term use for wound healing in epidermolysis bullosa.
- What could go wrong
- This is an observational study, not a controlled trial, so it can only suggest links, not prove cause and effect. Results may take years and could be inconclusive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA, DYSTROPHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Toulouse, Hôpital Larrey
RECRUITINGToulouse, France
-
Guy's and St Thomas' NHS Foundation Trust
RECRUITINGLondon, United Kingdom
-
Hospital Clinic, Barcelona
RECRUITINGBarcelona, Spain
-
Hospital San Juan de Dios (Barcelona)
RECRUITINGBarcelona, Spain
-
Hospital of Skin and Venereal Diseases of Thessaloniki
RECRUITINGThessaloniki, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.